Screener
Rigel Pharmaceuticals RIGL Q2 2026 earnings
Reported August 4, 2026 · After market close
Revenue$78.7MBeat by $23.4M
EPS$0.88Beat by $0.79
Revenue estimate$55.3M
EPS estimate$0.09
“Rigel delivered a strong second quarter, highlighted by record net product sales, continued profitability and the in-license of VEPPANU, the first and only FDA-approved PROTAC for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. We expect VEPPANU to be commercially available later this month, further expanding our commercial business in hematology and oncology. We are also advancing the development of R289 in our ongoing Phase 1b study in patients with R/R lower-risk MDS, and remain on track to complete enrollment in the dose expansion phase of the study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$80.1M
EPS estimate$0.92
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Rigel Pharmaceuticals report Q2 2026 earnings?
- Rigel Pharmaceuticals (RIGL) reported Q2 2026 earnings on August 4, 2026 after market close.
- What were Rigel Pharmaceuticals's Q2 2026 revenue and EPS?
- Rigel Pharmaceuticals reported revenue of $78.7M and eps of $0.88 for Q2 2026.
- Did Rigel Pharmaceuticals beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $55.3M by $23.4M. EPS beat the consensus estimate of $0.09 by $0.79.
- How did Rigel Pharmaceuticals's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 22.6% from $101.7M a year earlier and eps declined 73.2% from $3.28.
- Where can I find Rigel Pharmaceuticals's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001034842-26-000053) and the 10-Q periodic report (0001034842-26-000052) directly on SEC EDGAR. The filing index links above go to sec.gov.
